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Abstract
Background: SLC/CCL21, normally expressed in high endothelial venules and in T cell zones of
spleen and lymph nodes, strongly attracts T cells and dendritic cells (DC). We have previously
shown that SLC/CCL21-mediated anti-tumor responses are accompanied by significant induction
of IFNγ and the CXC chemokines, monokine induced by IFNγ (MIG/CXCL9) and IFNγ-inducible
protein-10 (IP-10/CXCL10).
Results: We assessed the importance of IFNγ, IP-10/CXCL10 and MIG/CXCL9 in SLC/CCL21
therapy. In vivo depletion of IP-10/CXCL10, MIG/CXCL9 or IFNγ significantly reduced the anti-
tumor efficacy of SLC/CCL21. Assessment of cytokine production at the tumor site showed an
interdependence of IFNγ, MIG/CXCL9 and IP-10/CXCL10; neutralization of any one of these
cytokines caused a concomitant decrease in all three cytokines. Similarly, neutralization of any one
of these cytokines led to a decrease in the frequency of CXCR3+ve T cells and CD11c+ve DC at
the tumor site.
Conclusion: These findings indicate that the full potency of SLC/CCL21-mediated anti-tumor
responses require in part the induction of IFNγ, MIG/CXCL9 and IP-10/CXCL10.
Background
SLC/CCL21, normally expressed in high endothelial
venules and in T cell zones of spleen and lymph nodes,
strongly attracts T cells and dendritic cells (DC) [1–8].
SLC/CCL21 recruits both naïve lymphocytes and antigen
stimulated DC into T cell zones of secondary lymphoid
organs, co-localizing these early immune response con-
stituents that culminate in cognate T cell activation [1].
The capacity to facilitate the co-localization of both DC
and T cells forms a strong rationale for the use of SLC/
CCL21 in cancer therapy. In previous studies we have
shown that the SLC/CCL21-mediated anti-tumor respons-
es are accompanied by the enhanced elaboration of IFNγ,
IP-10/CXCL10, MIG/CXCL9, GM-CSF and IL-12, but
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decreased PGE2, VEGF, IL-10, and TGF-β at the tumor site
[9,10]. In addition, there was a marked increase in CD4+
and CD8+ cells secreting IFNγ and GM-CSF as well as DC
expressing CD11c infiltrating the tumors. MIG/CXCL 9
and IP-10/CXCL10 are glutamine-leucine-arginine (ELR)-
negative CXC chemokines that are potent chemoattract-
ants for activated T cells [11–13]. These chemokines also
have in common the ability to signal through a G protein-
coupled receptor, CXCR3, expressed on activated T lym-
phocytes. IP-10/CXCL10, MIG/CXCL9 and IFNγ are
known to have potent anti-tumor activities in vivo [14–
17]. Both MIG/CXCL9 and IP-10/CXCL10 are important
for the anti-tumor activity mediated by IFNγ inducing cy-
tokines such as IL-12 [16,18,19]. Based on these findings
we hypothesized that augmentation in IFNγ, MIG/CXCL9,
and IP-10/CXCL10 would play an important role in the
SLC/CCL21-mediated anti-tumor response. Here we
show that the cytokines IFNγ, IP-10/CXCL10 and MIG/
CXCL9 serve as effector molecules in SLC/CCL21-mediat-
ed anti-tumor responses.
Results and Discussion
Host antigen presenting cells (APC) are critical for the
cross-presentation of tumor antigens [20]. However tu-
mors have the capacity to limit APC maturation, function
and infiltration of the tumor site [21–24]. Thus molecules
that attract host APC and T cells could serve as potent
agents for cancer immunotherapy. A potentially effective
pathway to restore Ag presentation is the establishment of
a chemotactic gradient that favors localization of both ac-
tivated DC and Type 1 cytokine producing lymphocytes at
the tumor site. SLC/CCL21, a CC chemokine expressed in
high endothelial venules and in T cell zones of spleen and
lymph nodes, strongly attracts naive T cells and DCs [1–
8]. Because DCs are potent APCs that function as principal
activators of T cells, the capacity to facilitate the co-locali-
zation of both DC and T cells may reverse tumor-mediat-
ed immune suppression and orchestrate effective cell-
mediated immune responses [9,10,25–27]. In addition to
its immunotherapeutic potential, SLC/CCL21 has been
found to have potent angiostatic effects [28], thus adding
further support for its use in cancer therapy. Based on
these dual capacities, we as well as others have begun pre-
clinical evaluation of SLC/CCL21 in several tumor models
[9,10,25–27].
Utilizing two transplantable murine lung cancer models,
we have previously shown that the anti-tumor efficacy of
SLC/CCL21 is T cell-dependent [9]. In both models re-
combinant SLC/CCL21 administered intratumorally led
to complete tumor eradication in 40 % of the treated
mice. Studies performed in CD4 and CD8 knockout mice
also revealed a requirement for both CD4 and CD8 lym-
phocytes subsets for SLC/CCL21 mediated tumor regres-
sion. Consistent with these findings we found that SLC
therapy did not alter tumor growth in SCID mice. In im-
mune competent mice, intratumoral injection of SLC/
CCL21 led to a significant increase in CD4 and CD8 T
lymphocytes as well as DC infiltrating the tumor and the
draining lymph nodes. The cellular infiltrates were accom-
panied by an enhanced elaboration of IL-12, IFNγ, IP-10/
CXCL10 and MIG/CXCL9 at the tumor site [9].
SLC/CCL21 is documented to have direct anti-angiogenic
effects [28,29]; the tumor reductions observed in this
model could have been due to participation by T cells se-
creting IFNγ leading to inhibition of angiogenesis via
MIG/CXCL9 and IP-10/CXCL10, as well as T cell-depend-
ent immunity [16]. IFNγ mediates a range of biological ef-
fects that facilitate anticancer immunity. MIG/CXCL9 and
IP-10/CXCL10 are potent angiostatic factors that are in-
duced by IFNγ [14,16,17]. Both MIG/CXCL9 and IP-10/
CXCL10 are chemotactic for stimulated CXCR3-express-
ing activated T lymphocytes that could further amplify
IFNγ at the tumor site [30]. Hence we postulated that in
addition to IFNγ, IP-10/CXCL10 and MIG/CXCL9 would
also be important contributors to the tumor reduction in
the context of SLC/CCL21 therapy.
Figure 1
10 5 3 LL tumors were implanted in C57Bl/6 mice. 5 days fol-
lowing tumor implantation, mice were treated intratumorally 
with recombinant murine SLC/CCL21 (0.5 µg) 3X/week. 
One day before SLC/CCL21 administration, mice were given 
the respective cytokine antibody by i.p. injection. The anti-
bodies were administered three times per week. Antibodies 
to: IP-10/CXCL10, MIG/CXCL9 and IFNγ significantly inhib-
ited the antitumor efficacy of SLC/CCL21 (*p < 0.01 com-
pared to the control antibody treated group). n = 8 mice 
group
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To determine the importance of MIG/CXCL9, IP-10/
CXCL10 and IFNγ in the SLC/CCL21 mediated antitumor
response, these cytokines were depleted in SLC/CCL21-
treated mice. Anti-IP-10/CXCL10, MIG/CXCL9 and IFNγ
antibodies each partially but yet significantly inhibited
the anti-tumor efficacy of SLC/CCL21 (Figure 1 * p < 0.01
compared to the control antibody group). Neutralization
of IFNγ caused a significant decrease in both MIG/CXCL9
and IP-10/CXCL10 indicating that these chemokines are
largely IFNγ dependent. Thus, an increase in IFNγ at the
tumor site of SLC/CCL21-treated mice could explain the
relative increases in IP-10/CXCL10 and MIG/CXCL9. The
converse was also observed; IFNγ production at the tumor
site was found to be MIG/CXCL9- and IP-10/CXCL10-de-
pendent as indicated by the fact that neutralization of
these cytokines caused a significant decrease in IFNγ(Fig-
ure 2). Neutralization of any one of these cytokines
caused a concomitant decrease in all three cytokines, thus
indicating that IFNγ, MIG/CXCL9 and IP-10/CXCL10 are
interdependent in the SLC/CCL21-mediated anti-tumor
responses. Based on these findings, we speculated that the
decrease of IP-10/CXCL10 and MIG/CXCL9 led to a de-
crease in IFNγ by limiting the influx of T cells producing
IFNγ at the tumor site. Because MIG/CXCL9 and IP-10/
CXCL10 are chemotactic for stimulated CXCR3 expressing
activated T lymphocytes, we determined if neutralizing
these chemokines in vivo in the SLC/CCL21-treated mice
would decrease the frequency of CXCR3 expressing T cells
at the tumor sites. Compared to SLC/CCL21-treated mice
receiving control antibody, flow cytometric evaluation of
single-cell suspensions of non-necrotic tumors from SLC/
CCL21-treated mice receiving neutralizing antibodies to
MIG/CXCL9, IP-10/CXCL10 and IFNγ showed 10, 12 and
31 % decreases, respectively, in the gated CD3 CXCR3+ve
T cell populations (Table 1). The fact that neutralization
of IFNγ was the most efficient at decreasing the total
number of CXCR3-activated T cells may be due to the de-
crease in the IFNγ-dependent CXCR3 ligands MIG/CXCL9
and IP-10/CXCL10. Individually, neutralizing MIG/
CXCL9 and/or IP-10/CXCL10 only led to a partial de-
crease in the total number of CXCR3-activated T cells. Be-
cause MIG/CXCL9 and IP-10/CXCL10 share the same
receptor (CXCR3), one possible explanation of a partial
decrease in CXCR3-activated T cells is that neutralization
of one ligand may overexpose the receptor to the other lig-
and. Furthermore, because murine SLC/CCL21 binds
CXCR3 receptor, SLC/CCL21 may be recruiting CXCR3+ve
T cells directly. An alternative explanation is that residual
cytokines such as IFN-inducible T cell α chemoattractant
(ITAC/CXCL11) present after in vivo neutralization of IF-
Nγ, MIG, IP-10 may have remaining activity and attract
CXCR3+ve T cells. Our results imply that all 3 cytokines,
IFNγ, MIG and IP-10 play interrelated roles in the recruit-
ment of CXCR3-activated T cells in SLC/CCL21-mediated
anti-tumor responses. While the number of CD4 and CD8
cells remained unaltered, compared to SLC/CCL21-treat-
ed mice receiving control antibody, mice administered
neutralizing antibodies to MIG/CXCL9, IP-10/CXCL10
and IFNγ showed respective decreases of 38, 28 and 16%
in the number of CD11c+ DEC205+ DC infiltrating the tu-
mor (Table 1). At present it is not clear why there is a de-
crease in DC following neutralization of MIG/CXCL9, IP-
10/CXCL10 and IFNγ. A plausible explanation is that
these cytokines may be involved in complex interactions
with other molecules that are chemotactic for DC. Further
studies are required to delineate the mechanisms respon-
sible for MIG/CXCL9, IP-10/CXCL10 and IFNγ mediated
localization of DC at the tumor site.
Conclusions
Our results suggest that the anti-tumor properties of SLC/
CCL21 may be due to its chemotactic capacity in co-local-
ization of DC and T cells as well as in part to the induction
of key cytokines such as IFNγ, IP-10/CXCL10 and MIG/
CXCL9.
Figure 2
SLC/CCL21-treated mice had a significant induction in IFNγ, 
MIG/CXCL9 and IP-10/CXCL10 at the tumor site compared 
to diluent treated control tumor bearing mice (p < 0.001). 
Assessment of cytokine production at the tumor site of SLC/
CCL21 treated mice receiving anti-IFNγ, anti MIG/CXCL9 
and anti IP-10/CXCL10 showed an interdependence of IFNγ, 
MIG/CXCL9 and IP-10/CXCL10: neutralization of any one of 
these cytokines in vivo caused a concomitant decrease in all 
three cytokines (*p < 0.01 compared to the control antibody 
treated group). Results are expressed as pg/mg of total pro-
tein. Total protein was determined by the Bradford assay. n= 
8 mice per group
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Materials and Methods
Reagents
Abs to murine IFNγ, recombinant IFNγ were obtained
from PharMingen (San Diego, CA). Abs to murine MIG/
CXCL9, IP-10/CXCL10 and recombinant cytokine stand-
ards was purchased from R&D (Minneapolis, MN). Re-
combinant SLC/CCL21 was obtained from PeproTech.
(Rocky Hill, NJ). Polyclonal goat anti-murine MIG/
CXCL9 and anti-murine IP-10/CXCL10 specific anti-se-
rum were produced and characterized as previously de-
scribed [31]. Anti-mouse IFNγ monoclonal (R4-462,
American Type Culture Collection, Rockville, Maryland,
MD) neutralizing antibody was purified by affinity chro-
matography from SCID mice ascites, which was generated
3–4 weeks after intraperitoneal injection of 106 R4-462
hybridoma cells per mouse [32]. For flow cytometry, la-
beled antibodies (FITC, PE, PerCP) against the T cell sur-
face markers to CD3, CD4, CD8 and against the DC
markers, CD11c and DEC 205 and the appropriate con-
trols were purchased from PharMingen. FITC labeled anti-
rabbit IgG was purchased from PharMingen. Rabbit anti-
mouse CXCR3 antibody was purchased from Zymed Lab-
oratories Inc. (So. San Francisco, CA). Murine serum albu-
min (Sigma, St. Louis, MO) was utilized as control
injections for SLC/CCL21.
Cell culture and tumorigenesis model
A weakly immunogenic lung cancer, Lewis lung carcino-
ma (3LL, H-2b) obtained from ATCC (CRL-1642, LLC)
was utilized for assessment of cytokines important for
SLC/CCL21 – mediated anti-tumor responses in vivo. The
cells were routinely cultured as monolayers in 25 cm3 tis-
sue culture flasks containing RPMI 1640 medium (Irvine
Scientific, Santa Anna, CA) supplemented with 10% fetal
bovine serum (FBS) (Gemini Bioproducts, Calabasas,
CA), penicillin (100 U/ml), streptomycin (0.1 mg/ml), 2
mM glutamine (JRH Biosciences, Lenexa, KS) and main-
tained at 37°C in a humidified atmosphere containing
5% CO2 in air. The cell lines were mycoplasma free and
cells were utilized up to the tenth passage before thawing
frozen stock cells from liquid N2.
For tumorigenesis experiments, 105 3LL tumor cells were
inoculated by s.c. injection in the right supra scapular area
of C57Bl/6 mice and tumor volumes were monitored
three times each week. Five day established tumors were
treated with intratumoral injection of 0.5 µg of recom-
binant murine SLC/CCL21 (Pepro Tech, Rocky Hill, NJ)
or murine serum albumin (utilized as an irrelevant pro-
tein for control injections) were administered three times
per week for two weeks as previously described [9]. 24 h
prior to SLC/CCL21 treatment, and then three times a
week, mice were injected i.p. with 1 ml/dose of anti-IP-10/
CXCL10, or anti-MIG/CXCL9, or 100 µg/dose of purified
monoclonal anti-IFNγ or appropriate control antibodies
(goat IgG and rat IgG) at equivalent doses for the duration
of the experiment. In response to these antibodies, there
was a significant reduction of the respective cytokines in
vivo (Figure 2). Tumor volume was calculated as previous-
ly described [9].
Cytokine ELISA
MIG/CXCL9, IP-10/CXCL10 and IFNγ were quantified us-
ing a modification of a double ligand method as previous-
ly described [33].
Flow Cytometry
Flow cytometric analyses for T cell and DC markers were
performed on a FACScan flow cytometer (Becton Dickin-
son, San Jose, CA) in the University of California, Los An-
Table 1: Neutralization of IP-10, MIG and IFNγ reduces the frequency of CD3+CXCR3+ T lymphocytes and CD11C+ DEC205+ DC at the 
tumor site of SLC/CCL21-treated mice
+ Anti IP-10 + Anti MIG + Anti IFNγ + anti Control Ab Diluent Control
% MCF % MCF % MCF % MCF % MCF
CD4 13 44 14 47 13 40 *13 42 *6 48
CD8 35 57 34 55 32 50 *33 52 *26 52
CD3CXCR3 **28 58 **27 57 **23 55 * 34 59 *12 58
CD11C+DEC 205+ **10 111 **9 110 **11 101 *14 105 *4 100
Single cell suspensions of non-necrotic tumor nodules from SLC/CCL21 treated mice receiving neutralizing antibodies to P-10/CXCL10, MIG/
CXCL9, IFNγ, control Ab and diluent treated tumor bearing mice were prepared. Cell surface staining for T cell markers CD4, CD8, CD3, and the 
chemokine receptor CXCR3 as well as DC markers CD11C and DEC205 were evaluated by flow cytometry. Cells were identified as lymphocytes 
or DC by gating on the forward and side scatter profiles; 10,000 gated events were collected and analyzed using Cell Quest software. Within the 
gated T lymphocyte population, intratumoral injection of SLC/CCL21 led to an increase in the frequency of CD4+, CD8+, CD3+CXCR3+ events 
compared to the diluent control (*p < 0.001). Within the gated DC population, intratumoral injection of SLC/CCL21 led to an increase in the fre-
quency of CD11C+DEC205+ events compared to the diluent control (*p < 0.001). Compared to SLC/CCL21-treated mice receiving control anti-
body, mice receiving neutralizing antibodies to IP-10/CXCL10, MIG/CXCL9, and IFNγ showed decrease in the gated CD3+CXCR3+ T cell as well as 
CD11C+DEC205 + DC events (**p < 0.01) (n = 8 mice per group). MCF is mean channel fluorescence intensity. CD3+CXCR3+ MCF is for CXCR3. 
CD11C+DEC205+, MCF is for DEC205.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/22
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geles, Jonsson Cancer Center Flow Cytometry Core
Facility. Cells were identified as lymphocytes or DC by
gating based on forward and side scatter profiles.
CD11c+ve DCs were defined as the bright populations
within tumor nodules. 10,000-gated events were collected
and analyzed using Cell Quest software (Becton Dickin-
son). For staining, two or three fluorochromes (PE, FITC,
PerCP) (PharMingen) were used to gate on the CD3, CD4
and CD8 T lymphocyte population or CD11c +ve DC in
single cell suspensions from tumor nodule. For CXCR3
expression, T cells were doubly stained for CD3 and
CXCR3 cell surface markers.
Statistical Analysis
Groups of 8 mice were used. Statistical analyses of the data
in figures 1, 2 and in table 1 were performed using the
paired Student t test.
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